Trial
NCT05788289
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Incyte Corporation
Condition
Mantle Cell Lymphoma
Intervention
Tafasitamab
Why stopped
Slow accrual rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-25